Clinical Trials

Pfizer Announces COVID-19 Antiviral Pill

Last Friday, Pfizer announced that the clinical trial for their COVID-19 antiviral pill, Paxlovid, demonstrated high efficacy in preventing severe COVID-19 in at-risk persons. Paxlovid is unique and differs from Merck’s COVID-19 antiviral, Molnupiravir, by binding to enzymes responsible for the replication of SARS-CoV-2 and inhibiting its life cycle.

Read More »

Merck Submits COVID Antiviral Pill for EUA

This morning, the pharmaceutical company Merck submitted an application for EUA of their COVID-19 oral antiviral pill. If accepted, this will become the first pill authorized by the FDA to treat COVID-19. Other FDA authorized COVID-19 treatments must be administered intravenously or via injection.

Read More »

AstraZeneca Submits EUA for COVID Antibody Prophylaxis

AstraZeneca released a press release today stating that their long-acting antibody (LAAB) combination, AZD7442, has been shown to reduce the risk of symptomatic Covid-19 by 77% in a clinical trial. The trial included many participants who had medical conditions placing them at greater risk of severe illness and those who had not been producing sufficient antibodies after vaccination.

Read More »